Last reviewed · How we verify

NCT06830122

Effects of Lactobacillus Crispatus LCr86 on Bacterial Vaginosis and Ovarian Function in Women

Not yet recruiting NA Last updated 17 February 2025
What this trial tests

NA trial testing Probiotic in Patients With Bacterial Vaginosis in 60 participants. Not yet recruiting.

Timeline
20 March 2025
Primary endpoint
30 September 2025
30 April 2026

Quick facts

Lead sponsorWecare Probiotics Co., Ltd.
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date20 March 2025
Primary completion30 September 2025
Estimated completion30 April 2026

Drugs / interventions tested

Conditions studied

Sponsor

Wecare Probiotics Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, female only, with Patients With Bacterial Vaginosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lactobacillus crispatus LCr86 was selected as a test preparation to observe its clinical efficacy in an intervention trial of combined antibiotic treatment and evaluate its effect on the cure rate, recurrence rate and vaginal flora of patients with bacterial vaginitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Probiotic

Trials testing the same drug.

Other Wecare Probiotics Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06830122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing